In this context and as reproducible results for FAK activation were obtained both in aspirates and tumor specimens, p‐FAK‐Y397 shows promise as a potential biomarker to be assessed in tumor specimen or aspirates, to determine tumor aggressiveness and potential responsiveness to FAK kinase inhibition. Here, PTK2 is linked to neoplasm.